Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
about
APE1/Ref-1 regulates PTEN expression mediated by Egr-1Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein HopTime- and dose-dependent effects of curcumin on gene expression in human colon cancer cellsA phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerTherapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.Mitochondria in the elderly: Is acetylcarnitine a rejuvenator?A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells.In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).Epigenetic targets of bioactive dietary components for cancer prevention and therapy.Connectedness of PPI network neighborhoods identifies regulatory hub proteins.Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulationMetabolism as a key to histone deacetylase inhibition.Epigenetic alterations in ultraviolet radiation-induced skin carcinogenesis: interaction of bioactive dietary components on epigenetic targetsHistone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells.Histone deacetylase 1 is required for the development of the zebrafish inner ear.Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer.Chemical regulation of epigenetic modifications: opportunities for new cancer therapy.Apoptosis induction by sulfur-containing compounds in malignant and nonmalignant human cells.Global histone profiling by LC-FTMS after inhibition and knockdown of deacetylases in human cellsMicroRNA Dysregulation in Colon Cancer Microenvironment Interactions: The Importance of Small Things in Metastases.Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia.Impact of Epigenetic Dietary Components on Cancer through Histone Modifications.Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.Processing of DNA double strand breaks by alternative non-homologous end-joining in hyperacetylated chromatinType-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.Synthesis of a novel series of benzylether-containing cinnamoyl derivatives as histone deacetylase inhibitors.Gastric cancer cell lines induced by trichostatin A.Effect of broccoli intake on markers related to oxidative stress and cancer risk in healthy smokers and nonsmokers.Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylasesSulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm.Characterisation of the GRAF gene promoter and its methylation in patients with acute myeloid leukaemia and myelodysplastic syndrome.Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors.Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells.Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis.Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.
P2860
Q24650473-7B46764B-23D5-4731-AAC4-63103FCA73CCQ24682945-53247BEA-9721-4B8B-B40A-4760F5300CEDQ24792777-2AC40342-517F-4137-BBFC-68BED66FF867Q33384180-680640E8-6296-4BD1-A79E-4F67765EAEAFQ33583208-8C5B3E59-772C-4BDA-BD32-FD7FA588F5AFQ33659166-CE9C6AFD-80A5-4468-A60B-02EBE5964AB4Q33869272-273C274E-477E-48EF-9969-0051FFC4C15AQ33996663-EB314002-EA7F-48B4-8D36-BFA5B6749706Q34099365-35E7121C-D2EA-4E29-98C2-B767ED100C79Q34173886-3E41ECB7-5779-4E9E-84F0-08C446D245C3Q34175788-E43B3CF4-5395-455B-A454-79E081243979Q34508252-B7B23D97-2CE1-427E-9114-35B757844285Q34771449-10A875E6-5DCE-4A54-ADAF-11938402AA4EQ35126359-4F075C45-51A4-42EC-B196-2F1F8097E3E2Q35661981-D1910936-5338-4543-9FF6-6A6577456FA6Q35782828-7AA4B051-DF50-4E3A-8CB1-39792EA975DDQ36162556-89C3D13F-39B1-419A-AD5F-630BA82DF704Q36179533-04E91921-2244-4F0B-A642-03C8CF820EB6Q36400882-CB6B67BF-9593-4703-A58A-B3BC29219312Q36527064-8C8E3314-CDC8-4B2E-8F4A-D35BFAA7F913Q36570605-9679D33B-E847-4130-AD3A-1890141D9710Q37083432-6A55FD17-798B-454D-812F-6A47FFFD81C9Q37377789-AD926635-1B6B-4B6A-8536-B1059030F6F9Q37438475-11854AA4-AF22-4EBF-97E3-44053FA0C8E1Q37930489-88CA17DB-985B-4955-A5E0-68656492FEDAQ38141135-8D9610C5-CA36-4DA8-9DE9-F390965248F0Q38428453-DE79724D-071F-45EA-AE07-9809E7FD99BBQ38785012-CA48430A-6CBD-4E91-AA70-79F04DCE21C6Q39293918-821ACBA4-D706-48C8-8458-D169CBAEDEBCQ39755948-EE40B7FE-9F6A-4D46-A8C5-EC50F3F3BDCFQ39832667-9154D1FB-A85E-4510-8D22-EAD855F41B84Q39948191-AA572F80-2E1E-43F6-8C23-FA15F9F5BC05Q40000704-B22FBD7B-F59F-4178-BE39-2050CC3EACEAQ41128716-813CEE48-2873-430A-8AD1-36BFCA2AC17FQ41748065-9BACA254-80C1-40A4-9228-DD68A82ABA9CQ42123629-ABEBDE6A-78EE-49A4-B3BB-2C0F43B31D7CQ42815519-DE94F800-CB79-4B51-9F91-34784D2526C1Q43066875-A9DF497A-9CB1-4CAC-966E-D0E38F17A177Q43176974-867E40BA-4F24-4E0B-A3E2-590B90FD0B0BQ43520664-ED4CE2DC-D6C1-46E3-9E94-5F237DD8EDE4
P2860
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
@ast
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
@en
type
label
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
@ast
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
@en
prefLabel
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
@ast
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
@en
P2093
P1433
P1476
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
@en
P2093
Dong Hoon Kim
Ho Jeong Kwon
Minjung Kim
P304
P356
10.5483/BMBREP.2003.36.1.110
P577
2003-01-01T00:00:00Z